Amgen and The University of Texas MD Anderson Cancer Center announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE) antibody constructs Read the full story

Amgen and Kite Pharma have entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies Read the full story

Amgen and LabCentral biopharma partners: announced an agreement in which Amgen has become a LabCentral platinum sponsor. Read the full story

The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

Onyx Pharmaceuticals is a biotechnology company based in San Francisco developing therapies for the treatment of people living with cancer. Read the full story

Amgen is a top biotechnology company based in Thousand Oaks, CA, USA Read the full story

Merck  has signed three separate pharma partnering clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Merck’s investigational anti-PD-1 immunotherapy. Read the full story

Illumina has entered into an pharma deal agreement with Amgen to develop and commercialize a multigene, NGS-based test as a companion diagnostic for Vectibix (panitumumab). Read the full story

Carmot Therapeutics has entered into a collaboration and pharma license agreement with Amgen. Read the full story

Amgen biopharma partners by acquiring Roche's rights to the neutropenia drugs filgrastim and pegfilgrastim, effective January 1, 2014 Read the full story